Flecainide Acetate

DRUG4 trials

Sponsors

University Medical Center Hamburg-Eppendorf, Eastern Cooperative Oncology Group, Vanderbilt University Medical Center, InCarda Therapeutics, Inc.

Conditions

Catecholaminergic Polymorphic Ventricular TachycardiaPainParoxysmal Atrial Fibrillation (PAF)acute ischemic stroke and atrial fibrillation (AF)

Phase 2

Flecainide in Treating Patients With Chronic Neuropathic Pain

CompletedNCT00002996

Eastern Cooperative Oncology GroupPain

Start: 1998-05-04Target: 20Updated: 2023-06-15

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

CompletedNCT03539302

InCarda Therapeutics, Inc.Paroxysmal Atrial Fibrillation (PAF)

Start: 2018-05-29End: 2022-01-17Updated: 2024-05-14

Phase 4

Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)

RecruitingCTIS2025-521260-35-00

University Medical Center Hamburg-Eppendorfacute ischemic stroke and atrial fibrillation (AF)

Start: 2025-11-07Target: 1035Updated: 2025-10-28

Unknown Phase

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

CompletedNCT01117454

Vanderbilt University Medical CenterCatecholaminergic Polymorphic Ventricular Tachycardia

Start: 2011-12-31End: 2015-12-31Updated: 2017-06-14

Related Papers

Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm

JACC. Clinical electrophysiology2024-04-1014 citations

Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm

Circulation Arrhythmia and Electrophysiology2022-02-2421 citations

Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

JAMA Cardiology2017-07-01166 citations